10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
REGENERON PHARMACEUTICALS, INC. | ||
Ticker: REGN Fiscal Year: 2016 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2016 10-K (Filed: Feb 9, 2017) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2016 | Dec 31, 2015 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $ 535,203 | 809,102 |
| Marketable securities | 503,481 | 236,121 |
| Accounts receivable - trade, net | 1,343,368 | 1,152,489 |
| Accounts receivable from Sanofi | 92,989 | 153,152 |
| Accounts receivable from Bayer HealthCare | 175,263 | 162,152 |
| Inventories | 399,356 | 238,578 |
| Prepaid expenses and other current assets | 130,528 | 163,501 |
| Total current assets | 3,180,188 | 2,915,095 |
| Marketable securities | 864,260 | 632,162 |
| Property, plant, and equipment, net | 2,083,421 | 1,594,120 |
| Deferred tax assets | 825,303 | 461,945 |
| Other assets | 20,294 | 5,810 |
| Total assets | 6,973,466 | 5,609,132 |
| LIABILITIES and STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | 879,096 | 644,112 |
| Capital Lease Obligations | 127,274 | 0 |
| Deferred revenue from Sanofi, current portion | 115,267 | 101,573 |
| Deferred revenue - other, current portion | 116,397 | 51,914 |
| Other current liabilities | 3,461 | 13,563 |
| Total current liabilities | 1,241,495 | 811,162 |
| Deferred revenue from Sanofi | 503,474 | 582,664 |
| Deferred revenue - other | 327,298 | 82,015 |
| Facility lease obligations | 351,569 | 362,919 |
| Other long term liabilities | 100,385 | 115,535 |
| Total liabilities | 2,524,221 | 1,954,295 |
| Commitments and contingencies (Note 12) | ||
| Stockholders' equity: | ||
| Preferred Stock | 0 | 0 |
| Additional paid-in capital | 3,029,993 | 3,099,526 |
| Retained earnings | 1,748,222 | 852,700 |
| Accumulated other comprehensive (loss) income | (12,840) | 8,572 |
| Treasury Stock | (316,240) | (306,069) |
| Total stockholders' equity | 4,449,245 | 3,654,837 |
| Total liabilities and stockholders' equity | 6,973,466 | 5,609,132 |
| Class of Stock | ||
| Class A Stock | ||
| Common stock | 2 | 2 |
| Total stockholders' equity | 2 | 2 |
| Common Stock | ||
| Common stock | 108 | 106 |
| Total stockholders' equity | 108 | 106 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2016 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |